Medicare Enrolled
Dr. Raman Sood, M.D.
Medical Oncology · Dunkirk, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sood from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sood?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sood
Dr. Raman Sood is a medical oncology specialist in Dunkirk, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Sood performed 13,949 Medicare services across 821 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sood received a total of $213,836 from 91 pharmaceutical and/or device companies across 1301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sood is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in NY
$213,836 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,949
Medicare services
Top 6% in NY for medical oncology
821
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~697 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,050 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,812 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 832 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 740 | $1 | $10 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
556 | $8 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
417 | $65 | $135 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
289 | $91 | $175 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
242 | $12 | $50 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
198 | $1 | $5 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
186 | $99 | $240 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
83 | $22 | $65 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
72 | $1 | $5 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
68 | $50 | $110 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
62 | $10 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
61 | $10 | $45 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
61 | $22 | $80 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
61 | $1 | $5 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
60 | $41 | $100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
49 | $135 | $215 |
| New patient office visit, complex (60-74 min) | 29 | $161 | $290 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
21 | $126 | $240 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.4% high complexity
85.0% medium
10.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$213,836
Total received (2018-2024)
Avg $30,548/year across 7 years
Top 9% in NY for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
91
Companies
1,301
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$136,308 (63.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$61,106 (28.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,834 (7.4%)
Other
Charitable contributions, space rental, and other categories
$589 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$29,133
2023
$33,143
2022
$35,487
2021
$28,726
2020
$20,659
2019
$25,194
2018
$41,495
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$23,125
AstraZeneca Pharmaceuticals LP
$3,996
Merck Sharp & Dohme LLC
$227
Janssen Biotech, Inc.
$202
Novartis Pharmaceuticals Corporation
$167
PFIZER INC.
$149
GlaxoSmithKline, LLC.
$104
Takeda Pharmaceuticals U.S.A., Inc.
$102
Rigel Pharmaceuticals, Inc.
$95
Astellas Pharma US Inc
$95
Celgene Corporation
$77
Genentech USA, Inc.
$75
Lilly USA, LLC
$67
Daiichi Sankyo Inc.
$59
Incyte Corporation
$58
Eisai Inc.
$50
GENZYME CORPORATION
$47
ARRAY BIOPHARMA INC
$44
BeiGene USA, Inc.
$44
EMD Serono, Inc.
$44
PharmaEssentia USA Corporation
$40
ADC Therapeutics America, Inc.
$35
Aveo Pharmaceuticals, Inc.
$35
Bayer Healthcare Pharmaceuticals Inc.
$34
Ipsen Biopharmaceuticals, Inc
$30
Regeneron Healthcare Solutions, Inc.
$23
ABBVIE INC.
$21
JAZZ PHARMACEUTICALS INC.
$20
SOBI, INC
$18
Invivyd Inc
$17
Tempus AI, Inc
$17
SpringWorks Therapeutics, Inc.
$16
Top 3 companies account for 93.9% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$114,457
Celgene Corporation
$18,592
AstraZeneca Pharmaceuticals LP
$13,375
AbbVie, Inc.
$8,701
GENZYME CORPORATION
$6,910
Takeda Pharmaceuticals U.S.A., Inc.
$6,458
Epizyme, Inc.,
$6,196
Exelixis Inc.
$6,075
Incyte Corporation
$5,805
Janssen Biotech, Inc.
$5,051
GlaxoSmithKline, LLC.
$2,893
Novartis Pharmaceuticals Corporation
$2,263
Rigel Pharmaceuticals, Inc.
$1,678
Janssen Scientific Affairs, LLC
$1,619
Amgen Inc.
$1,338
Aveo Pharmaceuticals, Inc.
$1,106
Bayer HealthCare Pharmaceuticals Inc.
$1,104
PFIZER INC.
$1,011
BeiGene USA, Inc.
$828
Astellas Pharma US Inc
$666
Merck Sharp & Dohme Corporation
$662
Genentech USA, Inc.
$656
Merck Sharp & Dohme LLC
$627
Lilly USA, LLC
$615
Kite Pharma, Inc.
$419
Alexion Pharmaceuticals, Inc.
$317
Pharmacyclics LLC, An AbbVie Company
$313
Eisai Inc.
$224
Daiichi Sankyo Inc.
$215
Novocure GmbH
$200
Gilead Sciences, Inc.
$188
Clovis Oncology, Inc.
$143
ARRAY BIOPHARMA INC
$142
Boehringer Ingelheim Pharmaceuticals, Inc.
$134
Sun Pharmaceutical Industries Inc.
$130
Sirtex Medical Inc
$129
EISAI INC.
$128
AVEO Pharmaceuticals, Inc.
$121
JAZZ PHARMACEUTICALS INC.
$118
Seagen Inc.
$118
MorphoSys, US Inc.
$111
Horizon Therapeutics plc
$111
Agios Pharmaceuticals, Inc.
$98
Bayer Healthcare Pharmaceuticals Inc.
$96
AbbVie Inc.
$93
PharmaEssentia USA Corporation
$88
ADC Therapeutics America, Inc.
$82
SANOFI-AVENTIS U.S. LLC
$82
Regeneron Healthcare Solutions, Inc.
$77
EMD Serono, Inc.
$75
Acceleron Pharma, Inc.
$75
ABBVIE INC.
$72
Kyowa Kirin, Inc.
$71
SUN PHARMACEUTICAL INDUSTRIES INC.
$68
CTI BioPharma Corp.
$62
Mirati Therapeutics, Inc.
$62
US Oncology Corporate, Inc.
$60
Karyopharm Therapeutics Inc.
$48
Apellis Pharmaceuticals, Inc.
$47
Jazz Pharmaceuticals Inc.
$47
Ipsen Biopharmaceuticals, Inc
$47
TESARO, Inc.
$42
Dova Pharmaceuticals
$34
Coherus Biosciences Inc.
$31
Fresenius Kabi USA, LLC
$23
SERVIER PHARMACEUTICALS LLC
$22
Pharmacyclics LLC, an AbbVie Company
$20
Verastem, Inc.
$20
Deciphera Pharmaceuticals Inc.
$20
Genmab U.S., Inc.
$20
Myriad Genetic Laboratories, Inc.
$19
Myovant Sciences Inc.
$18
SOBI, INC
$18
Stemline Therapeutics Inc.
$18
Invivyd Inc
$17
Novocure Inc.
$17
Taiho Oncology, Inc.
$17
Tempus AI, Inc
$17
TG Therapeutics, Inc.
$16
SpringWorks Therapeutics, Inc.
$16
TG THERAPEUTICS, INC.
$15
Foundation Medicine, Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$14
Puma Biotechnology, Inc.
$14
Teva Pharmaceuticals USA, Inc.
$14
Adaptive Biotechnologies Corporation
$13
Helsinn Therapeutics (U.S.), Inc.
$13
Acrotech Biopharma LLC
$12
Tactile Systems Technology Inc
$11
Lexicon Pharmaceuticals, Inc.
$11
Janssen Pharmaceuticals, Inc
$5
Top 3 companies account for 68.5% of all-time payments
Associated products mentioned in payments ›
AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aranesp · Avastin · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CYMBALTA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · EXKIVITY · Empaveli · Enhertu · Erivedge · Erleada · FARESTON · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Gazyva · IBRANCE · ICLUSIG · IDHIFA · IM NAILS · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · JADENU · JAKAFI · JAYPIRCA · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MEKTOVI · MONJUVI · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · ODOMZO · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Oncology · Onivyde · Orserdu · PADCEV · PEMAZYRE · PEMGARDA · PIQRAY · PLUVICTO · POTELIGEO · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · RAYOS · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stimufend · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Truqap · Truxima · UKONIQ · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VIAGRA · VONJO · Venclexta · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · YONSA · Yescarta · ZEJULA · ZEPOSIA · ZEPZELCA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (64%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for medical oncology in NY.
Geographic Context
Medical oncologists within 10 mi
1
Per 100K population
0.8
County median income
$56,507
Nearest hospital
BROOKS-TLC HOSPITAL SYSTEM, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sood is a mixed practice specialist, with above-average Medicare volume (top 6% in NY), with speaking/promotional industry engagement in the top 9% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sood experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Sood performed 8,050 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sood receive payments from pharmaceutical companies?
Yes. Dr. Sood received a total of $213,836 from 91 companies across 1,301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sood's costs compare to other medical oncologists in Dunkirk?
Dr. Sood's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sood) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dunkirk
Browse medical oncologists in Dunkirk ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NY
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NY
Which NY medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology